Introduction of point-of-care testing in Japanese outpatient clinics is associated with improvement in time in therapeutic range in anticoagulant-treated patients

Circulation Journal

Volumn 78, Issue 6, 2014, Pages 1342-1348

  Okuyama, Yuji ^a,b   Matsuo, Miyuki ^c   Matsuo, Hiroshi ^c   Sakaguchi, Yoshihide ^d   Takai, Hiroyuki ^e   Horiguchi, Yasunori ^f   Ryomoto, Teruhiko ^g   Adachi, Seiji ^h   Amano, Toshio ⁱ   Togawa, Masaki ^j   Masuda, Masaharu ^b   Minamiguchi, Hitoshi ^b   Nanto, Shinsuke ^a,b   Komuro, Issei ^b,k   Sakata, Yasushi ^b  

^a Advanced Cardiovascular Therapeutics and Department of Cardiology   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Matsuo Clinic   (Japan)

^d Sakaguchi Medical Office   (Japan)

^e Takai Clinic   (Japan)

^f Horiguchi Clinic   (Japan)

^g Ryomoto Cardiovascular Clinic   (Japan)

^h Adachi Clinic   (Japan)

ⁱ Amanonaika Clinic   (Japan)

^j Togawa Clinic   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Outpatient clinic; Point of care testing; Prothrombin time internationalized normalized ratio; Time in therapeutic range; Warfarin

Indexed keywords

ANTITHROMBOCYTIC AGENT; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; FEMALE; HOSPITAL INFORMATION SYSTEM; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; POINT OF CARE TESTING; PROTHROMBIN TIME; TIME TO TREATMENT; CLINICAL TRIAL; MIDDLE AGED; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; PROTHROMBIN TIME; TIME FACTORS; WARFARIN;

EID: 84901310047     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1256     Document Type: Article

References (30)

1. Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: Results of the J-RHYTHM registry. Circ J 2013; 77: 2264-2270.
2. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
3. Inoue H, Nozawa T, Okumura K, Iwasa A, Lee JD, Shimizu A, et al. Attitudes of Japanese cardiologist toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. Circ J 2004; 68: 417-421.
4. Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2: 591-597.
5. Nakatani Y, Mizumaki K, Nishida K, Hirai T, Sakabe M, Oda Y, et al. Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients. Circ J 2012; 76: 317-321.
6. Rosendaal FR, Cannegieter SC, van der Mer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
7. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulation control: Results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245.
8. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
9. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J 2010; 74: 2479-2500.
10. Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation: A multicenter study of its status and influential factors. Circ J 2011; 75: 2087-2094.
11. Wieloch M, Hillarp A, Strandberg K, Nilsson C, Svensson PJ. Comparison and evaluation of a point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin. Thromb Res 2009; 124: 344-348.
12. Bardakci H, Altintas G, Faruk Cicek O, Kervan U, Yilmaz S, Kaplan S, et al. Comparison of the CoaguChek XS handheld coagulation analyzer and conventional laboratory methods measuring international normalized ratio (INR) values during the time to therapeutic range after mechanical valve surgery. J Card Surg 2013; 28: 254-257.
13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford M. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
14. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
15. Morgan C, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37-41.
16. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
17. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al; on behalf of the ACTIVE W investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
18. van Walreven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest 2006; 129: 1155-1166.
19. Lane DA, Lip GYH. Maintaining therapeutic anticoagulation: The importance of keeping "within range". Chest 2007; 131: 1277-1279.
20. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-1647.
21. Oppenkowski TP, Murray ET, Sandhar H, Fitzmaurice DA. External quality assessment for warfarin dosing using computerized decision support software. J Clin Pathol 2003; 56: 605-607.
22. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: A randomized, controlled trial. Ann Intern Med 2000; 133: 687-695.
23. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: Results from the international normalized ratio adherence and genetics (IN-RANGE) study. Arch Intern Med 2007; 167: 229-235.
24. Rose AJ, Miller DR, Ozonoff A, Berlowitz DR, Ash AS, Zhao S, et al. Gaps in monitoring during oral anticoagulation, insights into care transitions, monitoring barriers, and medication nonadherence. Chest 2013; 143: 751-757.
25. Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: A quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes 2011; 4: 276-282.
26. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go A, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752.
27. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; on behalf of the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
28. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; on behalf of the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
29. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al; on behalf of the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
30. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-2191.